EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model
Rhythm
AFIB: A SILENT CAUSE OF HEART FAILURE AND STROKE
*** September is National Atrial Fibrillation Awareness Month *** SAN FRANCISCO, Sept. 17, 2024 /PRNewswire/ — BACKGROUND: We all know someone who’s had a heart scare – an unusual flutter or disconcerting palpitations. The potential cause? A little-known and often silent heart health…
Vektor Medical Unveils Groundbreaking Research on AI and Deep Learning Innovations in Ventricular Tachycardia Analysis
September 06, 2024 07:59 AM Eastern Daylight Time ATLANTA–(BUSINESS WIRE)–Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, will present findings today at HRX 2024. The two studies showcase how Vektor’s advanced technologies uniquely leverage AI and deep learning to assess wall thickness and scar tissue in ventricular tachycardia […]
Medtronic EV ICD global pivotal trial final results demonstrate high ATP success and effective defibrillation: ESC Congress 2024
Benefits of transvenous implantable defibrillators, including anti-tachycardia pacing (ATP), in a single device implanted safely outside the vascular space: 77% ATP success rate, in line with transvenous ICDs Avoided shocks in nearly half of all ventricular tachycardia/ventricular fibrillation (VT/VF) episodes through 30.6 months average follow-up LONDON and GALWAY, Sept. […]
Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.
Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress
ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia.
DRAI MARTINI: Artificial Intelligence Beats Human Readers at Arrhythmia Detection
WARSAW, Poland, Sept. 2, 2024 /PRNewswire/ — New research presented at the ESC Congress 2024 reveals that a novel artificial intelligence (AI) algorithm has significantly higher sensitivity than human specialists in detecting heart rhythm disorders on long ECG recordings. The DRAI…
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Food and Drug Administration (FDA) has cleared BioCardia to market the Morph DNA Steerable Introducer product family, subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act.
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard […]
PaceMate® Acquires Medtronic Paceart Optima™ System, Bringing Complementary Capabilities to Cardiac Data Management
August 27, 2024 08:00 AM Eastern Daylight Time SARASOTA, Fla.–(BUSINESS WIRE)–PaceMate®, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from Medtronic (NYSE: MDT.) This strategic move significantly expands PaceMate’s reach globally, adding nearly 1,000 clinic locations worldwide. This […]
Recent
Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors
Corify Care Receives FDA Clearance for ACORYS® — Introducing Instant, 4-D Electroanatomical Cardiac Mapping in Real-time
Rapid Medical™ Announces FDA Clearance of TIGERTRIEVER™ 25 and First Clinical Cases
Popular
- No commented posts yet